oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic...
30
Transcript of oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic...
![Page 1: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/1.jpg)
![Page 2: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/2.jpg)
![Page 3: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/3.jpg)
![Page 4: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/4.jpg)
![Page 5: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/5.jpg)
![Page 6: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/6.jpg)
![Page 7: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/7.jpg)
![Page 8: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/8.jpg)
![Page 9: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/9.jpg)
![Page 10: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/10.jpg)
![Page 11: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/11.jpg)
![Page 12: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/12.jpg)
![Page 13: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/13.jpg)
![Page 14: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/14.jpg)
![Page 15: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/15.jpg)
![Page 16: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/16.jpg)
![Page 17: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/17.jpg)
![Page 18: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/18.jpg)
![Page 19: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/19.jpg)
![Page 20: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/20.jpg)
![Page 21: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/21.jpg)
![Page 22: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/22.jpg)
![Page 23: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/23.jpg)
![Page 24: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/24.jpg)
![Page 25: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/25.jpg)
![Page 26: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/26.jpg)
![Page 27: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/27.jpg)
![Page 28: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/28.jpg)
![Page 29: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/29.jpg)
![Page 30: oncologypro.esmo.org...Tao 1671." 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy](https://reader030.fdocuments.in/reader030/viewer/2022040813/5e5868227ac70105366b9088/html5/thumbnails/30.jpg)